Last reviewed · How we verify

CN NGANOU-GNINDJIO, MD, MSc — Portfolio Competitive Intelligence Brief

CN NGANOU-GNINDJIO, MD, MSc pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ferric polymaltose hydroxide complex IM Ferric polymaltose hydroxide complex IM marketed
Iron Sucrose IV Iron Sucrose IV marketed Iron replacement agent Transferrin receptor (indirect); iron supplementation Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. American Regent, Inc. · 1 shared drug class
  4. Azad Pharma AG · 1 shared drug class
  5. China-Japan Friendship Hospital · 1 shared drug class
  6. Hallym University Medical Center · 1 shared drug class
  7. J. Uriach and Company · 1 shared drug class
  8. JW Pharmaceutical · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CN NGANOU-GNINDJIO, MD, MSc:

Cite this brief

Drug Landscape (2026). CN NGANOU-GNINDJIO, MD, MSc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cn-nganou-gnindjio-md-msc. Accessed 2026-05-17.

Related